Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.59 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.59 |
| ▸ | CCR4 | P51679 | 1/20 | 0.56 |
| ▸ | PDE5A | O76074 | 2/20 | 0.53 |
| ▸ | ACP1 | P24666 | 2/20 | 0.53 |
| ▸ | OGG1 | O15527 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4912379 | 1.00 | KCNN2 (0.59) | KCNN2KCNN3CCR4PDE5AACP1 | |
| SCHEMBL4913903 | 1.00 | KCNN2 (0.59) | KCNN2KCNN3CCR4PDE5AACP1 | |
| SCHEMBL4911365 | 0.99 | KCNN2 (0.57) | KCNN2KCNN3CCR4PDE5AACP1 | |
| SCHEMBL4910336 | 0.94 | ALDH1A1 (0.51) | KCNN2KCNN3CCR4PDE5AACP1 | |
| SCHEMBL4913809 | 0.90 | ALDH1A1 (0.51) | KCNN2KCNN3CCR4ACP1ALDH1A1 | |
| SCHEMBL4913744 | 0.89 | KDM4E (0.48) | KCNN2KCNN3CCR4ACP1ALDH1A1 | |
| SCHEMBL4911767 | 0.89 | CYP1A2 (0.55) | KCNN2KCNN3CCR4ALDH1A1LMNA | |
| SCHEMBL4913314 | 0.87 | MAPK1 (0.45) | KCNN2KCNN3CCR4ACP1ALDH1A1 | |
| SCHEMBL4913876 | 0.86 | GBA1 (0.55) | KCNN2KCNN3ALDH1A1NPSR1KMT2A | |
| SCHEMBL22872865 | 0.84 | KCNN2 (0.56) | KCNN2KCNN3CCR4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861388-B1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | SANIONA AS (DK) | 2017-07-05 | — | — | EP | claimed |
| US-8252806-B2 | 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-propylamine; 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-(4-morpholin-4-yl-phenyl)-amine; respiratory diseases, epilepsy, convulsions, seizures, gastrointestinal dysfunction, ischaemia, psychosis, schizophrenia, anxiety, depression, Alzheimer's disease | NEUROSEARCH A/S (DK) | 2012-08-28 | — | — | US | claimed |
| US-20080275045-A1 | Potassium Channel Modulating Agents and Their Medical Use | NEUROSEARCH A/S (DK) | 2008-11-06 | — | — | US | claimed |
| CN-101115736-A | Potassium channel modulating agents and their medical use | NEUROSEARCH AS (DK) | 2008-01-30 | — | — | CN | claimed |
| EP-1861388-A1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097441-A1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-09-21 | — | — | WO | claimed |
| EP-1861388-B1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | SANIONA AS (DK) | 2017-07-05 | — | — | EP | disclosed |
| US-8252806-B2 | 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-propylamine; 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-(4-morpholin-4-yl-phenyl)-amine; respiratory diseases, epilepsy, convulsions, seizures, gastrointestinal dysfunction, ischaemia, psychosis, schizophrenia, anxiety, depression, Alzheimer's disease | NEUROSEARCH A/S (DK) | 2012-08-28 | — | — | US | disclosed |
| US-20080275045-A1 | Potassium Channel Modulating Agents and Their Medical Use | NEUROSEARCH A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| CN-101115736-A | Potassium channel modulating agents and their medical use | NEUROSEARCH AS (DK) | 2008-01-30 | — | — | CN | disclosed |
| EP-1861388-A1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097441-A1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275045-A1 | Potassium Channel Modulating Agents and Their Medical Use | KCND2, KCNN3, KCNJ2 | KCNN2 4/4885KCNN3 2/4885CCR4 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.